
ICON (ICLR) Stock Forecast & Price Target
ICON (ICLR) Analyst Ratings
Bulls say
Icon is well-positioned to benefit from the growing demand for CRO services and management's focus on their core business and AI strategy. The company has set ambitious environmental targets and is diversely staffed, but there are concerns about potential accounting issues. In a downside scenario, the stock could reach $77, while in an upside scenario, it could reach $164, with a base case price target of $123.
Bears say
Icon is facing negative operating leverage due to past commercial softness and is investing in technology and efficiency initiatives. Positive bookings performance and partnerships in the biotech industry are driving factors in their outlook, along with an investment in Banyan BioInnovations. However, concerns about accounting practices and the potential for revenue restatements should be taken into consideration. ICON is well-positioned in the growing clinical trial industry, but the negative outlook suggests caution in terms of potential risks and uncertainties.
This aggregate rating is based on analysts' research of ICON and is not a guaranteed prediction by Public.com or investment advice.
ICON (ICLR) Analyst Forecast & Price Prediction
Start investing in ICON (ICLR)
Order type
Buy in
Order amount
Est. shares
0 shares